|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
|
30948344 |
2020 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
|
30644143 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eribulin inhibited the growth of 4 TERT promoter mutation-harboring glioblastoma cell lines in vitro at subnanomolar concentrations.
|
31099446 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutation was observed in 7/17 patients with diffuse astrocytic glioma, IDH-wild type; recently-defined as "molecular GBM."
|
31639630 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations occur in the majority of glioblastoma, bladder cancer (BC), and other malignancies while the ETS family transcription factors GABPA and its partner GABPB1 activate the mutant TERT promoter and telomerase in these tumors.
|
31802036 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
|
30187121 |
2018 |
|
LOC110806263
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report the genetic landscape of TERTp<sup>WT</sup>-IDH<sup>WT</sup> glioblastoma and identify SMARCAL1 inactivating mutations as a novel genetic mechanism of ALT.
|
29802247 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results highlight the critical role of GABPβ1L in enabling immortality in TERT promoter mutant glioblastoma.
|
30205050 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Importantly, glioblastoma multiforme (GBM) patient tumors bearing TERT promoter mutations (C228T and C250T) known to be associated with increased telomerase activity; exhibited elevated Nrf2 and TKT expression and decreased glycogen accumulation.
|
27148686 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We detected specific (-124 C>T and -146 C>T) TERT promoter mutations in 143/178 (80.3%) primary GBM and 4/14 (28.6%) secondary GBM (P < .001).
|
25140036 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-6 (IL-6) expression regulated by TERT promoter status and polymorphism, what leads us to think that TERT and IL-6 plays a significant role in GBM, where specific SNPs increase the risk of developing GBM while the rs2853669 SNP and specific mutations in the TERT promoter of the tumor lead to shorter survival.
|
26143636 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH1/2 wild-type gliomas and glioblastoma-like genomic alterations, including gain on chromosome arm 7q (+7q), loss on chromosome arm 10q (-10q), TERT promoter mutation and oncogene amplification, displayed the worst outcome.
|
25783747 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventy-three percent of GBM patients harbored TERT promoter mutations associated with enhanced telomerase activity and TERT mRNA expression but reduced telomere lengths (P < .001 for all).
|
25681309 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations were highly frequent in glioblastoma (83.9%), urothelial carcinoma (64.5%), oligodendroglioma (70.0%), medulloblastoma (33.3%) and hepatocellular carcinoma (31.4%).
|
25843513 |
2015 |
|
LOC110806263
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations.
|
23887589 |
2013 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Originally described in melanoma, the mutations in TERT promoter have been shown to be common in certain other tumor types that include glioblastoma, hepatocellular carcinoma, and bladder cancer.
|
24101484 |
2013 |